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1641However, recently reported data from the ABSORB II
study (ABSORB II Randomized Controlled Trial)
demonstrated that the results of angina evaluation
based on the SAQ can differ quite signiﬁcantly from
site-diagnosed angina/chest pain. Nonetheless, the
investigators considered the latter a clinically valu-
able parameter and reported it in detail (4).
Although we recognize certain limitations of our
straightforward approach of chest pain assessment,
we feel that the data obtained are of interest and
presume that they are clinically meaningful.*Clemens von Birgelen, MD, PhD
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First in Humans Study of Gastric Artery
Embolization for Weight LossObesity is associated with adverse cardiovascular and
metabolic conditions. Dietary, medical, or surgical
weight loss strategies are frequently unsuccessful and
accompanied by risks. Although many appetite-
limiting hormones have been discovered, only 1 hor-
mone, ghrelin, has been shown to be orexigenic
(appetite stimulating) (1). Ghrelin-producing cells are
located in the fundus of the stomach; through ghrelin
secretion, these cells stimulate appetite, resulting in
weight gain (1). Several animal studies have shown
that embolization of arteries supplying the gastric
fundus reduces serum ghrelin levels and food intake
(2–4). In addition, signiﬁcant weight loss has been
demonstrated in humans after left gastric artery
embolization to treat active upper gastrointestinal
bleeding (5). The aim of this prospective, single-armft Gastric Artery
Contrast injection outlines the celiac trunk (CT), common hepatic
tive left gastric artery angiography. A microcatheter (MC) has been
artery for support. (C) Selective angiography of the left gastric artery.
ted (arrows).
TABLE 1 Baseline Characteristics (N ¼ 5)
Female/male 1/4
Age, yrs 44.7  7.4
Weight, kg 128.1  24.4
Body mass index, kg/m2 42.2  6.8
Ghrelin, pg/ml 473.4  189.11
Values are n or mean  SD.
TABLE 2 Weight Los
Patient #
Initial
Weight, kg
1 119
2 165
3 98
4 131
5 127
Mean 128  24
p Value
Values are mean  SD. p Va
calculated by the Wilcoxon
FU ¼ follow-up.
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1642study was an initial evaluation of the safety and efﬁ-
cacy of left gastric artery embolization with the intent
to reduce plasma ghrelin levels and body weight. The
study was approved by the local ethics committee.
On August 2, 2012, the ﬁrst procedure was
conducted at the Cardiovascular Department of
N. Kipshidze Central University Hospital (Tbilisi,
Georgia) (N.K., A.A). After 6-F femoral arterial access,
a 6-F Heartrail II JR-4.0 guide catheter (Terumo
Europe N.V., Leuven, Belgium) was used to engage
the celiac trunk, and angiography was performed to
identify the origin and anatomy of the left gastric
artery. In some cases, a 0.35-inch guidewire was
advanced into the common hepatic or splenic artery
to stabilize the guide catheter position. The left
gastric artery, a branch of the celiac trunk, was wired
with a 0.014-inch Runthrough NS PTCA Guide Wire
(Terumo Europe N.V.), and an Excelsior 1018 Micro-
catheter (Boston Scientiﬁc Corp., Cork, Ireland) was
advanced over the guidewire into the mid-segment of
the left gastric artery. Subsequently, the guidewire
was removed while maintaining the microcatheter
position in the mid-left gastric artery, and selective
angiography was performed to ensure proper catheter
position and allow deﬁnition of the anatomy and
course of the left gastric artery (Figures 1A and 1B).
Repeat injections of small amounts of BeadBlocks Results: Individual and Mean Weight at Baseline and FU
Weight (kg)
At
1-Month FU
At
3-Month FU
At
6-Month FU
At
12-Month FU
At
20–24-Month FU
102 99 94 98 95
146 143 140 145 140
90 85 80 74 83
120 116 117 110 108
117 114 107 103 102
115  21 111  22 108  23 106  26 106  21
0.0032 0.0012 0.0008 0.0002 0.027
lues are calculated by the paired t test; p values at 1-, 3-, 6-, and 12-month follow-up
signed rank test are 0.043, 0.042, 0.042, 0.041, and 0.041, respectively.Embolic Bead, 300- to 500-mm compressible micro-
spheres (Biocompatibles UK Limited, Surrey, United
Kingdom) mixed with contrast (1:1 ratio) into the left
gastric artery were then performed with angiography
between injections to assess ﬂow characteristics.
Injections were continued until the distal branches of
the left gastric artery were no longer visible during
contrast injection (Figure 1C). The guidewire and
microcatheter were then withdrawn, and the patients
were transferred to a monitored unit where the
introducer sheath was removed and manual pressure
was applied to obtain hemostasis. All subsequent
embolizations were performed in a similar fashion.
All patients remained in the hospital until the ﬁrst
follow-up gastroscopy 1 day after the intervention. A
second follow-up gastroscopy was performed 1 week
after the procedure. Patients’ weights were measured
and body mass index calculated. For the duration of
the study, no speciﬁc instructions were given to
improve dietary habits and/or the level of physical
activity.
Statistical analysis was performed using SPSS
version 12.0 for Windows (Lead Technologies Inc.,
Chicago, Illinois). All values were presented as mean
 SD. Comparison of weight, body mass index, and
plasma ghrelin level between different time points
was done with the paired t test. In addition, a
Wilcoxon signed rank test was performed.
Baseline characteristics are outlined in Table 1.
There were no procedural complications, and all
patients were discharged after completion of the ﬁrst
follow-up gastroscopy on the day after the interven-
tion. Three of the 5 patients described mild transient
epigastric discomfort after the procedure. However,
follow-up gastroscopies were unremarkable. All pa-
tients reported a reduction in their appetite. Mean
weight was reduced by 10%, 13%, 16%, 17%, and 17%
at 1-, 3-, 6-, 12-, and 20- to 24-month follow-up,
respectively (p < 0.05, regardless of whether the
paired t test or Wilcoxon signed rank test was used for
calculation) (Table 2, Figure 2A). Blood ghrelin levels
were signiﬁcantly lower at 1- and 3-month follow-up
(by 29% and 36% from baseline, respectively, p <
0.05) and increased at 6-month follow-up compared
with 3-month follow-up while remaining 19% lower
than the baseline (p < 0.05, regardless of whether the
paired t test or Wilcoxon signed rank test was used for
calculation) (Table 3, Figure 2B). For 4 of the 5 pa-
tients, blood ghrelin levels were available at 12
months. These remained (21%) lower than baseline
levels (p < 0.05 with paired t test and 0.068 with
Wilcoxon signed rank test) (Table 3, Figure 2B).
Our results suggest that a weight reduction may be
achieved in obese patients by left gastric artery
FIGURE 2 Weight and Ghrelin at Follow-up
(A) Weight in kilograms over time in months. Individual weights are indicated by dashed lines and average weight (with SD) by a
solid line. (B) Ghrelin levels (pg/ml) over time in months. Individual levels are indicated by dashed lines and average levels (with SD) by a
solid line.
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1643embolization. The observed weight loss may be a
result of a reduction in ghrelin levels.
There are several limitations. First, the absence of
a control group does not allow deﬁnitive conclusions
regarding efﬁcacy. Although for the duration of the
study, participants were not supplied with any spe-
ciﬁc instructions to improve their dietary or exercise
habits, it is possible that the procedure and study
participation led to a higher motivation for diet con-
trol and exercise. However, in this case, an increase
rather than the observed decrease in plasma ghrelin
levels would be expected. Second, the intermediate-
term follow-up is too short to allow conclusions
regarding weight loss durability. A rebound phe-
nomenon mediated by a ghrelin level increase to
baseline levels causing recurrent weight gain is
conceivable. Third, using microparticles of interme-
diate size may limit reﬂux and collateral damage andTABLE 3 Ghrelin Results: Individual and Mean Ghrelin Levels at Base
Patient #
Initial Ghrelin
Level, pg/ml At 1-Month FU
1 460 313
2 486 326
3 446 380
4 501 342
5 478 342
Mean 471  21 341  20
p Values 0.0015
Values are mean  SD. p Values were calculated by the paired t test; p values at 1-, 3-,
0.043, 0.043, and 0.068, respectively.
FU ¼ follow-up; N/A ¼ not available.limit the degree of mucosal injury. However,
although there was no evidence by endoscopy for
gastritis or ulcer formation in the short term and no
symptoms to suggest gastritis throughout follow-up,
given the limited number of patients, the risk of
gastric ulcer formation may be signiﬁcant but too
small to have been observed in our study.
In conclusion, percutaneous left gastric artery
embolization with embolic beads as described in
our study appears safe. It leads to a reduction in
plasma ghrelin levels and is accompanied by a sig-
niﬁcant weight loss at intermediate-term follow-up.
Further studies with larger patient numbers and the
use of a dedicated device are needed to examine
the utility of this procedure and to determine
the best procedural technique that allows ghrelin
level reductions while minimizing the risk of ulcer
formation.line and FU
Ghrelin Level, pg/ml
At 3-Month FU At 6-Month FU At 12-Month FU
301 326 351
324 411 N/A
316 389 330
300 389 410
326 391 381
314  13 381  32 368  35
0.0002 0.0042 0.0055
6-, and 12-month follow-up calculated by the Wilcoxon signed rank test are 0.043,
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